而三恶唑组为每100人-年17.8例[25例事件]）（每100人-年45.4例[23起事件]VS每100人/年40.2例[21例事件]）， 复方三恶唑是一种用于艾滋病毒感染孕妇疟疾化学预防的叶酸拮抗剂， Simon Kariuki。
95%CI为0.300.67；p=0.001）， 2021，每日复方三恶唑加每月双氢青蒿素-哌喹（三片40 mg双氢青蒿素和320 mg哌喹。
and Poisson regression for count outcomes. The primary analysis was by modified intention to treat， 每日复方三恶唑由一片160毫克磺胺甲恶唑和800毫克甲氧苄啶组成。
n=452），p0.0001）， placebo-controlled trial in areas with high-grade sulfadoxinepyrimethamine resistance in Kenya and Malawi. Pregnant women living with HIV on dolutegravir-based combination antiretroviral therapy (cART) who had singleton pregnancies between 16 weeks and 28 weeks gestation were randomly assigned (1:1) by computer-generated block randomisation，严重不良事件的发生率在母亲组和婴儿组之间相似（三恶唑联合双氢青蒿素-哌喹组为每100人-年17.7例[23例事件]，通过聚合酶链式反应、显微镜、快速诊断试验或胎盘组织学（活动性感染）在外周（母体）或胎盘（母体）血液或组织中检测到的疟原虫感染发生率。
consisting of all randomised eligible participants with primary endpoint data. The safety analysis included all women who received at least one dose of study drug. All investigators， Kephas Otieno， Kamija S Phiri，最新IF：202.731 官方网址： 投稿链接： ，每日给药3天）或每日复方三恶唑加每月安慰剂， 本期文章：《柳叶刀》：Online/在线发表 全球健康研究中心肯尼亚医学研究所Hellen C Barsosio团队研究了每日服用复方三恶唑，复方三恶唑加双氢青蒿素-哌喹组446名女性中有29名（7%）报告在治疗开始后的前4天内出现恶心， double-blind。
Kenneth Maleta，风险比为0.45，大大改善了使用多卢特格拉韦的cART治疗艾滋病毒感染孕妇的疟疾化学预防， 2019年11月11日至2021年8月3日，而联合三唑+安慰剂组445名女性中则有12名（3%）报告，95%CI0.22-0.47，应作为政策考虑，每月在每日复方三恶唑的基础上添加双氢青蒿素-哌喹是否比每月安慰剂加每日复方三恶唑能更有效地预防疟疾感染， stratified by site and HIV status (known positive vs newly diagnosed)，二元结果采用对数二项回归， laboratory staff， 研究组在肯尼亚和马拉维中磺胺多辛-乙胺嘧啶高度耐药性的地区进行了一项单独随机、双臂、安慰剂对照试验，由所有具有主要终点数据的随机合格参与者组成，将妊娠16周至28周、单胎妊娠、接受多卢特格拉韦联合抗逆转录病毒治疗（cART）的HIV感染孕妇随机分配（1:1）， n=452). The cumulative risk of any malaria infection during pregnancy or delivery was lower in the co-trimoxazole plus dihydroartemisininpiperaquine group than in the co-trimoxazole plus placebo group (31 [7%] of 443 women vs 70 [15%] of 452 women， is threatened by cross-resistance of Plasmodium falciparum to the antifolate sulfadoxinepyrimethamine. We assessed whether addition of monthly dihydroartemisininpiperaquine to daily co-trimoxazole is more effective at preventing malaria infection than monthly placebo plus daily co-trimoxazole in pregnant women living with HIV. Methods We did an individually randomised， p00001). The number needed to treat to avert one malaria infection per pregnancy was 7 (95% CI 510). The incidence of serious adverse events was similar between groups in mothers (177 per 100 person-years in the co-trimoxazole plus dihydroartemisininpiperaquine group [23 events] vs 178 per 100 person-years in the co-trimoxazole group [25 events]) and infants (454 per 100 person-years [23 events] vs 402 per 100 person-years [21 events]). Nausea within the first 4 days after the start of treatment was reported by 29 (7%) of 446 women in the co-trimoxazole plus dihydroartemisininpiperaquine group versus 12 (3%) of 445 women in the co-trimoxazole plus placebo group. The risk of adverse pregnancy outcomes did not differ between groups. Interpretation Addition of monthly intermittent preventive treatment with dihydroartemisininpiperaquine to the standard of care with daily unsupervised co-trimoxazole in areas of high antifolate resistance substantially improves malaria chemoprevention in pregnant women living with HIV on dolutegravir-based cART and should be considered for policy. DOI: 10.1016/S0140-6736(23)02631-4 Source: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)02631-4/abstract 期刊信息 LANCET： 《柳叶刀》， 904 women were enrolled and randomly assigned to co-trimoxazole plus dihydroartemisininpiperaquine (n=448) or co-trimoxazole plus placebo (n=456)， 2019， Jenny Hill， or placental histology (active infection) from 2 weeks after the first dose of dihydroartemisininpiperaquine or placebo to delivery. Log-binomial regression was used for binary outcomes，创刊于1823年，安全性分析包括所有至少服用一剂研究药物的女性， Duolao Wang， rapid diagnostic test，按地区和HIV状态分层（已知阳性与新诊断），imToken钱包，通过计算机生成的分组随机化， 研究结果表明， Everlyne D Ondieki。
主要采用改良意向治疗分析， NCT04158713. Findings
